CLIN.L

Clinigen Group Plc
Clinigen Group plc - Block Listing Application
21st March 2022, 10:02
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4388F
Clinigen Group plc
21 March 2022
 

21 March 2022

Clinigen Group plc

Block Listing Application

Clinigen Group plc (AIM: CLIN) ('Clinigen' or the 'Company' or the 'Group'), the global pharmaceutical Services and Products company, announces that a block listing application has been made to the London Stock Exchange for 3,000,000 ordinary shares of 0.1 pence each ("Ordinary Shares") to be admitted to trading on AIM (the "Admission").  The Ordinary Shares that are being reserved under this block listing application will be issued by the Company, as required, in order to satisfy the exercise of share options pursuant to the terms of its share plans, including on or after the Court sanction of the proposed scheme of arrangement for the Company in connection with the acquisition of the Company by Triley Bidco Limited, which is scheduled to be heard on 31 March 2022.

It is expected that Admission of these Ordinary Shares will become effective on 23 March 2022. When issued, the Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares.

 

For more information, please contact:

Clinigen Group plc

+44 (0) 1283 495010

Shaun Chilton, Chief Executive Officer

Richard Paling, Interim Chief Financial Officer

Rob Fox, VP Investor Relations and Corporate Development

investors@clinigengroup.com



Numis Securities Limited - Nominated Adviser & Joint Broker

Tel: +44 (0) 20 7260 1000

James Black / Garry Levin / Freddie Barnfield

Clinigen@Numis.com

 

RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas




 

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Cole / Jessica Hodgson  

 

Tel: +44 (0) 20 3709 5700

Clinigen@consilium-comms.com

 



Notes to Editors

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products company focused on providing ethical access to medicines. Its' mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 20,000 healthcare professionals across more than 120 countries.

For more information on Clinigen, please visit http://www.clinigen.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ALSKFLBLLXLEBBK ]]>
TwitterFacebookLinkedIn